Roche / Genentech Patent-Cliff Exposure & CMS Drug Spending Portfolio

Roche / Genentech (South San Francisco, CA): 40 reconciled FDA prescription therapies (2.8% 2025 to 2030 cliff risk), $4.84B 2024 CMS Part D & Medicaid spend, and 53 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSouth San Francisco, CA
Reconciled FDA Portfolio Therapies40
2025 to 2030 Patent-Cliff Revenue Exposure2.8%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$4.84B
2024 Medicare Part D Spend$1.63B
2024 Medicaid Spend$3.22B
California HCAI SB 17 Filings53 WAC filings (max 23.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.